Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis

(Steve Stephenson) #1

http://www.thelancet.com/journals/landia/article/PIIS2213-8587(17)30412-6/fulltext?dgcid=etoc-edschoice_email_Dec

Example of industry funded study touting MARGINAL RELATIVE RISK advantages for their drugs.

Someone should calculate the ABSOLUTE RISK.

(VLC.MD) #2

in combined endpoints !

When your drug doesn’t help reduce specific events … see if it helps a collection of events.

(matt ) #3

Can you clean up this title? We can do it if that’s easier, just let us know.

Thanks.

(Steve Stephenson) #4

Looks like you did it.

(matt ) #5

Must have been another admin but done is done.